- Phare
- Validé par KD/KO
Anticorps Monoclonal anti-IL-6
IL-6 Monoclonal Antibody for WB, IF/ICC, ELISA
Hôte / Isotype
Mouse / IgG2b
Réactivité testée
Humain et plus (1)
Applications
WB, IHC, IF/ICC, ELISA
Conjugaison
Non conjugué
CloneNo.
1A3B4
N° de cat : 66146-1-Ig
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules MG U-87, cellules HUVEC, cellules Jurkat, Protéine recombinante |
| Résultats positifs en IF/ICC | cellules HUVEC traitées au LPS et à la bréfeldine A, |
Dilution recommandée
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:6000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:400-1:1600 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| KD/KO | See 1 publications below |
| WB | See 159 publications below |
| IHC | See 64 publications below |
| IF | See 33 publications below |
| ELISA | See 2 publications below |
Informations sur le produit
66146-1-Ig cible IL-6 dans les applications de WB, IHC, IF/ICC, ELISA et montre une réactivité avec des échantillons Humain
| Réactivité | Humain |
| Réactivité citée | Humain, porc |
| Hôte / Isotype | Mouse / IgG2b |
| Clonalité | Monoclonal |
| Type | Anticorps |
| Immunogène | IL-6 Protéine recombinante Ag10646 |
| Nom complet | interleukin 6 (interferon, beta 2) |
| Masse moléculaire calculée | 212 aa, 24 kDa |
| Poids moléculaire observé | 24 kDa |
| Numéro d’acquisition GenBank | BC015511 |
| Symbole du gène | IL6 |
| Identification du gène (NCBI) | 3569 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par protéine A |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
Interleukin-6 (IL-6) is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. IL-6 protein is secreted by a variety of cell types including T cells and macrophages as phosphorylated and variably glycosylated molecule. IL-6 plays an essential role in the final differentiation of B-cells into Ig-secreting cells involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. IL-6 is also considered a myokine, a cytokine produced from muscle, and is elevated in response to muscle contraction. IL-6 has been shown to interact with interleukin-6 receptor and glycoprotein 130. Additionally, IL-6 is involved in hematopoiesis, bone metabolism, and cancer progression, and has been defined an essential role in directing transition from innate to acquired immunity.
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for IL-6 antibody 66146-1-Ig | Download protocol |
| IF protocol for IL-6 antibody 66146-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Cell Metab Lighting up arginine metabolism reveals its functional diversity in physiology and pathology | ||
Nat Aging Single-cell and spatial RNA sequencing identify divergent microenvironments and progression signatures in early- versus late-onset prostate cancer | ||
Bioact Mater Angiogenesis, hemocompatibility and bactericidal effect of bioactive natural polymer-based bilayer adhesive skin substitute for infected burned wound healing | ||
Acta Pharm Sin B Ligand-based substituent-anchoring design of selective receptor-interacting protein kinase 1 necroptosis inhibitors for ulcerative colitis therapy | ||
Nat Commun Catalytically potent and selective clusterzymes for modulation of neuroinflammation through single-atom substitutions. |




